Cargando…

MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity

OBJECTIVE: To isolate and characterize muscle-specific kinase (MuSK) monoclonal antibodies from patients with MuSK myasthenia gravis (MG) on a genetic and functional level. METHODS: We generated recombinant MuSK antibodies from patient-derived clonal MuSK-specific B cells and produced monovalent Fab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huijbers, Maartje G., Vergoossen, Dana L., Fillié-Grijpma, Yvonne E., van Es, Inge E., Koning, Marvyn T., Slot, Linda M., Veelken, Hendrik, Plomp, Jaap J., van der Maarel, Silvère M., Verschuuren, Jan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410930/ https://www.ncbi.nlm.nih.gov/pubmed/30882021 http://dx.doi.org/10.1212/NXI.0000000000000547

Ejemplares similares

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis
por: Vergoossen, Dana L. E., et al.
Publicado: (2021)

Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK
por: Lim, Jamie L., et al.
Publicado: (2023)

MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine
por: Bhaskar, Shalini, et al.
Publicado: (2022)

MuSK-Associated Myasthenia Gravis: Clinical Features and Management
por: Rodolico, Carmelo, et al.
Publicado: (2020)

Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis
por: Kwon, Young Nam, et al.
Publicado: (2022)

Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis
por: Kim, Seung Woo, et al.
Publicado: (2017)

Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China
por: Zhang, Zunwei, et al.
Publicado: (2020)

Myasthenia gravis: MuSK MG, late-onset MG and ocular MG
por: Deymeer, Feza
Publicado: (2020)

Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes
por: Huang, Qi, et al.
Publicado: (2022)

Timing and localization of myasthenia gravis‐related gene expression
por: Vergoossen, Dana L. E., et al.
Publicado: (2021)

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment
por: Lanfranconi, S., et al.
Publicado: (2011)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
por: Schneider-Gold, Christiane, et al.
Publicado: (2017)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK
por: Yilmaz, Vuslat, et al.
Publicado: (2015)

Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis
por: Lee, Jae‐Yun, et al.
Publicado: (2016)

The impact of rituximab infusion protocol on the long‐term outcome in anti‐MuSK myasthenia gravis
por: Cortés‐Vicente, Elena, et al.
Publicado: (2018)

Anti-MuSK Positive Myasthenia Gravis with Anti-Lrp4 and Anti-titin Antibodies
por: Yamashita, Rika, et al.
Publicado: (2020)

Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis?
por: Bardakov, Sergey N., et al.
Publicado: (2022)

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
por: Vakrakou, Aigli G., et al.
Publicado: (2023)

Plasma Myokine Profiles in Patients With AChR- and MuSK-Ab-Positive Myasthenia Gravis
por: Seok, Jo Woon, et al.
Publicado: (2023)

SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
por: Huda, Saif, et al.
Publicado: (2019)

Laboratory Investigation of Hybrid IgG4 k/λ in MuSK Positive Myasthenia Gravis
por: Basile, Umberto, et al.
Publicado: (2021)

Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling
por: Otsuka, Kenji, et al.
Publicado: (2015)

Treating muscle-specific kinase myasthenia gravis from the inside out
por: Huijbers, Maartje G., et al.
Publicado: (2019)

Effects of the ß2-Adrenoceptor Agonist, Albuterol, in a Mouse Model of Anti-MuSK Myasthenia Gravis
por: Ghazanfari, Nazanin, et al.
Publicado: (2014)

Grave Prognosis of the MuscleSpecific Kinase (MuSK)-positive Myasthenia Gravis (MG): A False Prejudice
por: Hiew, Fu Liong
Publicado: (2020)

Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study
por: Meng, Xin, et al.
Publicado: (2022)

Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
por: Spagni, Gregorio, et al.
Publicado: (2022)

Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
por: Bastakoti, Sanjiv, et al.
Publicado: (2021)

Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis: Evidence for Cholinergic Neuromuscular Hyperactivity
por: Shin, Ha Young, et al.
Publicado: (2014)

Altered Active Zones, Vesicle Pools, Nerve Terminal Conductivity, and Morphology during Experimental MuSK Myasthenia Gravis
por: Patel, Vishwendra, et al.
Publicado: (2014)

Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated with Outpatient Periodic Weekly Blood Purification Therapy
por: Deguchi, Kentaro, et al.
Publicado: (2018)

Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis
por: Marino, Mariapaola, et al.
Publicado: (2020)

Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China
por: Zhou, Yufan, et al.
Publicado: (2022)

The formation of complex acetylcholine receptor clusters requires MuSK kinase activity and structural information from the MuSK extracellular domain
por: Mazhar, Sania, et al.
Publicado: (2012)

MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction
por: Cartaud, Annie, et al.
Publicado: (2004)

Mutations in MUSK causing congenital myasthenic syndrome impair MuSK–Dok-7 interaction
por: Maselli, Ricardo A., et al.
Publicado: (2010)

MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters
por: Koneczny, Inga, et al.
Publicado: (2013)

Anti-Muscle Specific Kinase (Anti-MuSK) Positive Myasthenia Gravis Overlapping With Parkinson’s Disease: A Challenging Diagnosis
por: Albassam, Mohammed S, et al.
Publicado: (2021)

Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravis
por: Ghazanfari, Nazanin, et al.
Publicado: (2015)

Comorbid Human Immunodeficiency Virus (HIV) and Muscle-Specific Kinase (MuSK) Myasthenia Gravis: A Case Report and Literature Review
por: Sherpa, Michael, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j2nu1h23mqh5tq3drl8j1gsrjc